You can read an exclusive article in @Svenska Dagbladet for the INNOVATIVA FÖRETAG edition, about our story and our pioneering technology, Abiprot, capable of delivering antibodies to the most difficult targeting classes of drugs has the potential to completely change the therapeutic landscape for millions of patients.
It was with this vision – to be able to make a big difference for patients who lack effective drugs today, that our founders @Owe and @Carolina launched Oblique Therapeutics in 2015.
To read the full article (in swedish) click here: https://innovationsverige.com/2021/10/06/abiprot-en-proteomikbaserad-antikroppsplattform-for-undruggable-targets/
To discover more about Abiprot in Science Advances :https://www.science.org/doi/10.1126/sciadv.abe6397
